Picture of Innocan Pharma logo

INNO Innocan Pharma Income Statement

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Annual income statement for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue000.0080.1962.56
Cost of Revenue
Gross Profit0.0030.1212.11
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses1.1734.737.688.82
Operating Profit-1.17-3-4.72-7.48-6.27
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-1.19-3.33-9.95-10.1-3.89
Provision for Income Taxes
Net Income After Taxes-1.19-3.33-9.95-10.1-3.89
Minority Interest
Net Income Before Extraordinary Items
Net Income-1.19-3.33-9.95-10-3.76
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-1.19-3.33-9.95-10-3.76
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.008-0.028-0.061-0.045-0.015
Dividends per Share